Glaucoma; Drugs
9
0
0
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
11.1%
1 terminated out of 9 trials
66.7%
-19.8% vs benchmark
44%
4 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?
Ocular Surface Disease and IOP Monitoring With Travoprost Without Conservatives
INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register
Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops
Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
CATS Tonometer IOP Reduction Latanoprost Verses Timolol
Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After Trabeculectomy
Evaluation of Adherence to Clinical Treatment of Glaucoma